JAK2 V617F与KIT D816V共存髓系肿瘤的临床与组织病理特征
本文报告45例同时携带JAK2 V617F和KIT D816V突变的髓系肿瘤患者,这两种突变分别见于>60%经典型MPN和>90%系统性肥大细胞增多症(SM)。70%患者存在脾大、血细胞减少、骨髓纤维化及额外体细胞突变等重叠特征;分子分析显示多数患者为两个独立克隆演化而非单克隆疾病。无额外高危突变者5年总生存率为77%。
要点
- JAK2 V617F与KIT D816V共存者常表现为MPN与SM特征重叠,70%有脾大、血细胞减少或骨髓纤维化。
- 分子分析提示多数患者两个突变来自独立克隆,而非同一克隆演化。
- 无额外高危突变(如SRSF2、ASXL1、RUNX1)者5年总生存率为77%。
核心结论
- JAK2 V617F与KIT D816V共存的髓系肿瘤常呈MPN与SM特征重叠,多数为两个独立克隆演化,无额外高危突变者5年总生存率77%。
研究设计与样本
- 回顾性报告45例同时携带JAK2 V617F和KIT D816V突变的髓系肿瘤患者,分析临床、形态学及分子学特征。
主要发现
- 所有45例均呈现MPN与SM各自典型特征的异质性组合,如白细胞/红细胞/血小板增多及乳酸脱氢酶升高(MPN),血清类胰蛋白酶及碱性磷酸酶升高(SM)。
- 70%患者存在重叠特征,包括脾大、血细胞减少、骨髓纤维化及额外体细胞突变。
- 分子分析显示两个突变的等位基因频率呈不一致发展,且单细胞来源集落不同时阳性,提示>60%受检者存在两个独立克隆而非单克隆疾病。
- 无额外高危突变(如SRSF2、ASXL1、RUNX1)的JAK2pos./KITpos.患者5年总生存率为77%。
关键数值与推荐
- JAK2 V617F在经典型MPN中检出率>60%,KIT D816V在系统性肥大细胞增多症中检出率>90%。
- 无额外高危突变者5年总生存率为77%。
临床怎么用
- 对MPN或SM患者应检测JAK2 V617F与KIT D816V共存情况,并评估额外高危突变以判断预后。
- 共存患者若伴脾大、血细胞减少或骨髓纤维化,需考虑两克隆独立演化的可能。
局限性
- 样本量45例,为回顾性分析,分子克隆性结论基于部分受检者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report on 45 patients with myeloid neoplasms and concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V (JAK2pos. /KITpos. ) mutations, which are individually identified in >60% of patients with classical myeloproliferative neoplasms (MPN) and >90% of patients with systemic mastocytosis (SM) respectively. In SM, the concurrent presence of a clonal non-mast cell neoplasm [SM with associated haematological neoplasm (SM-AHN)] usually constitutes a distinct subtype associated with poor survival. All 45 patients presented with a heterogeneous combination of clinical/morphological features typical of the individual disorders (e.g. leuco-/erythro-/thrombocytosis and elevated lactate dehydrogenase for MPN; elevated serum tryptase and alkaline phosphatase for SM). Overlapping features identified in 70% of patients included splenomegaly, cytopenia(s), bone marrow fibrosis and additional somatic mutations. Molecular dissection revealed discordant development of variant allele frequency for both mutations and absence of concurrently positive single-cell derived colonies, indicating disease evolution in two independent clones rather than monoclonal disease in >60% of patients examined. Overall survival of JAK2pos. /KITpos. patients without additional somatic high-risk mutations [HRM, e.g. in serine and arginine-rich splicing factor 2 (SRSF2), additional sex combs like-1 (ASXL1) or Runt-related transcription factor 1 (RUNX1)] at 5 years was 77%, indicating that the mutual impact of JAK2 V617F and KIT D816V on prognosis is fundamentally different from the adverse impact of additional HRM in the individual disorders.
引用
- Naumann N, Lübke J, Shomali W, et al. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. Br J Haematol. 2021. PMID: 34060083. doi:10.1111/bjh.17567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。